X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (265) 265
index medicus (237) 237
oncology (176) 176
male (153) 153
urology & nephrology (138) 138
cancer (133) 133
chemotherapy (122) 122
urology (102) 102
aged (84) 84
prostate cancer (79) 79
care and treatment (76) 76
middle aged (76) 76
treatment outcome (74) 74
metastasis (67) 67
female (65) 65
survival (64) 64
transitional-cell carcinoma (61) 61
prognosis (60) 60
bladder cancer (59) 59
antineoplastic agents - therapeutic use (56) 56
antineoplastic combined chemotherapy protocols - therapeutic use (56) 56
hematology, oncology and palliative medicine (50) 50
phase-ii trial (46) 46
retrospective studies (46) 46
docetaxel (45) 45
urothelial carcinoma (45) 45
aged, 80 and over (43) 43
cisplatin (43) 43
disease-free survival (42) 42
urinary bladder neoplasms - drug therapy (41) 41
immunotherapy (40) 40
survival analysis (38) 38
therapy (38) 38
urinary bladder neoplasms - pathology (38) 38
analysis (37) 37
phase-iii trial (37) 37
medical colleges (36) 36
neoplasm metastasis (36) 36
prostatic neoplasms - drug therapy (35) 35
carcinoma (34) 34
neoplasm staging (34) 34
research (34) 34
adult (33) 33
urologic neoplasms - drug therapy (33) 33
carcinoma, transitional cell - drug therapy (32) 32
abridged index medicus (31) 31
patient outcomes (31) 31
double-blind (30) 30
drug therapy (29) 29
radical cystectomy (28) 28
randomized controlled trials as topic (28) 28
medicine, general & internal (27) 27
animals (26) 26
trial (26) 26
urinary bladder neoplasms - surgery (26) 26
article (25) 25
gemcitabine (25) 25
health aspects (25) 25
kidney neoplasms - drug therapy (25) 25
prostatic neoplasms - pathology (25) 25
development and progression (24) 24
neoadjuvant chemotherapy (24) 24
phase-ii (24) 24
proportional hazards models (24) 24
bladder-cancer (23) 23
cisplatin - administration & dosage (23) 23
medicine & public health (23) 23
metastatic (23) 23
mitoxantrone plus prednisone (23) 23
open-label (23) 23
renal cell carcinoma (23) 23
antimitotic agents (22) 22
antineoplastic agents (22) 22
carcinoma, renal cell - drug therapy (22) 22
carcinoma, transitional cell - pathology (22) 22
clinical trials as topic (22) 22
cystectomy (22) 22
men (22) 22
paclitaxel (22) 22
risk factors (22) 22
urologic neoplasms - pathology (22) 22
urothelium - pathology (22) 22
urinary bladder neoplasms - mortality (21) 21
usage (21) 21
disease progression (20) 20
interferon-alpha (20) 20
prednisone (20) 20
prostatic neoplasms, castration-resistant - drug therapy (20) 20
cooperative-oncology-group (19) 19
gemcitabine plus cisplatin (19) 19
methotrexate (19) 19
neoadjuvant therapy (19) 19
pharmacology & pharmacy (19) 19
abiraterone acetate (18) 18
antineoplastic agents - adverse effects (18) 18
cisplatin - therapeutic use (18) 18
kaplan-meier estimate (18) 18
taxoids - administration & dosage (18) 18
urothelial cancer (18) 18
antineoplastic agents - administration & dosage (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 01/2014, Volume 32, Issue 1, p. 5
This review provides a broad overview of emerging data that provide hope that rational precision medicine for metastatic renal cell carcinoma (RCC) may be... 
Biological products industry | Metastasis
Journal Article
Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 01/2014, Volume 32, Issue 1, pp. 5 - 15
This review provides a broad overview of emerging data that provide hope that rational precision medicine for metastatic renal cell carcinoma (RCC) may be... 
Biomarkers | Renal cell carcinoma | Prognostic | Predictive
Journal Article
Urology, ISSN 0090-4295, 10/2017, Volume 108, p. 140
Journal Article
Urology, ISSN 0090-4295, 10/2017, Volume 108, pp. 140 - 141
Journal Article
Urology, ISSN 0090-4295, 10/2017, Volume 108, pp. 140 - 141
Journal Article
Urology, ISSN 0090-4295, 10/2017, Volume 108, pp. 140 - 141
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 11, pp. 1073 - 1074
For more than two decades, the only therapy that was proven to extend overall survival among patients with advanced urothelial carcinoma was cisplatin-based... 
TRIAL | MEDICINE, GENERAL & INTERNAL | CISPLATIN | PLUS | Carcinoma, Transitional Cell | B7-H1 Antigen | Urologic Neoplasms | Humans | Salvage Therapy | Adenocarcinoma | Care and treatment | Usage | Therapeutics | Homeopathy | Materia medica and therapeutics | Chemotherapy | Inhibitor drugs | PD-1 protein | Platinum | PD-L1 protein | Urothelial carcinoma | Urogenital system | Survival | Cisplatin | Regulatory approval | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 26, pp. 3228 - 3229
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2016, Volume 11, Issue 8, p. e0160924
Kinases are therapeutically actionable targets. Kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFR) and mammalian target of... 
INTERLEUKIN-2 | INTERFERON-ALPHA | ACTIVATION | EPHB2 EXPRESSION | EVEROLIMUS | PHOSPHORYLATION | MULTIDISCIPLINARY SCIENCES | RISK | RECURRENCE | SORAFENIB | CANCER | Up-Regulation | Kidney Neoplasms - genetics | Protein Kinases - genetics | Signal Transduction | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Gene Expression Profiling - methods | Male | Gene Expression Regulation, Enzymologic | Sequence Analysis, RNA - methods | Neoplasm Metastasis | Adult | Female | Aged | Physiological aspects | Development and progression | Genetic aspects | Carcinoma, Renal cell | Research | Gene expression | Phosphotransferases | TOR protein | Phosphates | Biotechnology | Phosphorylation | Target recognition | Genes | Nerve growth factor | Oncology | Genomes | Metastasis | Kinases | Medical diagnosis | Metastases | Signal transduction | Receptors | Salvage | Pathways | Cell cycle | Vascular endothelial growth factor | Medical research | NF-κB protein | Hematology | Rapamycin | Functional analysis | Preventive medicine | Growth factor receptors | Ribonucleic acid--RNA | Patients | Vascular endothelial growth factor receptors | Studies | Signaling | Ribonucleotides | Stem cells | Clear cell-type renal cell carcinoma | Tumors | Kidney transplantation | Cancer | RNA | Ribonucleic acid
Journal Article
Current Opinion in Urology, ISSN 0963-0643, 11/2017, Volume 27, Issue 6, pp. 542 - 546
Journal Article
Journal Article
Urology, 10/2017, Volume 108, p. 140
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 10/2019, Volume 28, Issue 10, pp. 821 - 826
Introduction: The conventional management of most patients with metastatic urothelial carcinoma (UC) is platinum-based chemotherapy followed by immunotherapy.... 
metastatic Urothelial carcinoma | Enfortumab vedotin | Nectin 4 | Antibody-drug conjugates
Journal Article
Urology, ISSN 0090-4295, 08/2017, Volume 106, pp. 124 - 124
Journal Article
Urology, ISSN 0090-4295, 08/2017, Volume 106, p. 124
Journal Article
Urology, ISSN 0090-4295, 08/2017, Volume 106, p. 124
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 419 - 421
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.